Peroxisome proliferator-activated receptor gamma (PPAR-gamma) (PPARG)

Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a member of the nuclear receptor superfamily of ligand-activated transcription factors that plays a pivotal role in regulating nutrient homeostasis [1]. It is primarily expressed in adipose tissue, where it functions as the master regulator of adipogenesis, driving the differentiation of mesenchymal stem cells into mature adipocytes [2]. By controlling the expression of genes involved in lipid uptake and storage, such as CD36 and adiponectin, PPAR-gamma effectively lowers circulating free fatty acids and improves systemic insulin sensitivity [3]. In clinical medicine, PPAR-gamma is the molecular target for the thiazolidinedione (TZD) class of drugs, which are used to manage type 2 diabetes by enhancing the body's response to insulin [5]. Beyond its metabolic functions, the receptor also modulates inflammatory responses by inhibiting the production of pro-inflammatory cytokines in macrophages and vascular cells [4].

Other names

PPAR-gammaPPARGNR1C3Glitazone receptorNuclear receptor subfamily 1 group C member 3

PPAR-gamma acts as a ligand-activated transcription factor. Upon binding an agonist, it undergoes a conformational change that allows it to heterodimerize with the Retinoid X Receptor (RXR). This complex then binds to specific DNA sequences known as Peroxisome Proliferator Response Elements (PPREs) in the promoter regions of target genes, recruiting co-activators to initiate the transcription of genes involved in lipid storage, glucose metabolism, and insulin sensitization [1][3][5].